SCHEMBL2897343

SCHEMBL2897343

CCOC(=O)CNc1cc2cc(Br)c(OCc3ccccc3)cc2cc1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
KMT2A Q03164 2/20 0.42
PPID Q08752 1/20 0.42
HTT P42858 1/20 0.42
PPIA P62937 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 2/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
BRD4 O60885 2/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LTA4H P09960 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL630140 0.87 MEN1 (0.48) KMT2APPIDL3MBTL1MAPTLMNA
SCHEMBL2892402 0.86 PTGER1 (0.48) SMN1; SMN2KMT2ATDP1L3MBTL1GAA
SCHEMBL4643473 0.83 LRRK2 (0.49) KMT2ABRD4RAB9ALMNAALDH1A1
SCHEMBL23539478 0.81 TDP1 (0.50) SMN1; SMN2KMT2ATDP1L3MBTL1GAA
SCHEMBL2889143 0.81 BRD4 (0.39) SMN1; SMN2KMT2APPIDHTTPPIA
SCHEMBL629377 0.79 LRRK2 (0.46) SMN1; SMN2HTTL3MBTL1GAABRD4
SCHEMBL31277431 0.79 LRRK2 (0.46) SMN1; SMN2HTTL3MBTL1GAABRD4
SCHEMBL30559871 0.79 TDP1 (0.50) SMN1; SMN2PPIATDP1L3MBTL1BRD4
SCHEMBL23539625 0.79 TDP1 (0.50) SMN1; SMN2PPIATDP1L3MBTL1BRD4
SCHEMBL29043357 0.78 TDP1 (0.49) SMN1; SMN2KMT2APPIATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252820-B2 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors NOVARTIS AG (CH) 2012-08-28 US disclosed
US-20100035942-A1 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors NOVARTIS AG (CH) 2010-02-11 US disclosed
EP-1963293-A1 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007067612-A1 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035942-A1 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors PTPRS, PTPRF, PTPRO SMN1; SMN2 1901/4885KMT2A 2339/4885PPID 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.